Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. / Wewer Albrechtsen, Nicolai J; Veedfald, Simon; Plamboeck, Astrid; Deacon, Carolyn F; Hartmann, Bolette; Knop, Filip K; Lauritsen, Tina Vilsbøll; Holst, Jens J.

I: Journal of Diabetes Research, Bind 2016, 8352957, 2016.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Wewer Albrechtsen, NJ, Veedfald, S, Plamboeck, A, Deacon, CF, Hartmann, B, Knop, FK, Lauritsen, TV & Holst, JJ 2016, 'Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion', Journal of Diabetes Research, bind 2016, 8352957. https://doi.org/10.1155/2016/8352957

APA

Wewer Albrechtsen, N. J., Veedfald, S., Plamboeck, A., Deacon, C. F., Hartmann, B., Knop, F. K., ... Holst, J. J. (2016). Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. Journal of Diabetes Research, 2016, [8352957]. https://doi.org/10.1155/2016/8352957

Vancouver

Wewer Albrechtsen NJ, Veedfald S, Plamboeck A, Deacon CF, Hartmann B, Knop FK o.a. Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. Journal of Diabetes Research. 2016;2016. 8352957. https://doi.org/10.1155/2016/8352957

Author

Wewer Albrechtsen, Nicolai J ; Veedfald, Simon ; Plamboeck, Astrid ; Deacon, Carolyn F ; Hartmann, Bolette ; Knop, Filip K ; Lauritsen, Tina Vilsbøll ; Holst, Jens J. / Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. I: Journal of Diabetes Research. 2016 ; Bind 2016.

Bibtex

@article{cc11eed9776743728f3c5bff35ed337d,
title = "Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion",
abstract = "Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, important. We studied the ability of immunoassays based on four different technologies to detect changes in levels of glucagon under conditions where glucagon levels are strongly suppressed. To our surprise, the most advanced technological methods, employing electrochemiluminescence or homogeneous time resolved fluorescence (HTRF) detection, were not capable of detecting the suppression induced by a glucose clamp (6 mmol/L) with or without atropine in five healthy male participants, whereas a radioimmunoassay and a spectrophotometry-based ELISA were. In summary, measurement of glucagon is challenging even when state-of-the-art immune-based technologies are used. Clinical researchers using glucagon as outcome measures may need to reconsider the validity of their chosen glucagon assay. The current study demonstrates that the most advanced approach is not necessarily the best when measuring a low-abundant peptide such as glucagon in humans.",
author = "{Wewer Albrechtsen}, {Nicolai J} and Simon Veedfald and Astrid Plamboeck and Deacon, {Carolyn F} and Bolette Hartmann and Knop, {Filip K} and Lauritsen, {Tina Vilsb{\o}ll} and Holst, {Jens J}",
year = "2016",
doi = "10.1155/2016/8352957",
language = "English",
volume = "2016",
journal = "Journal of Diabetes Research",
issn = "2314-6745",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion

AU - Wewer Albrechtsen, Nicolai J

AU - Veedfald, Simon

AU - Plamboeck, Astrid

AU - Deacon, Carolyn F

AU - Hartmann, Bolette

AU - Knop, Filip K

AU - Lauritsen, Tina Vilsbøll

AU - Holst, Jens J

PY - 2016

Y1 - 2016

N2 - Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, important. We studied the ability of immunoassays based on four different technologies to detect changes in levels of glucagon under conditions where glucagon levels are strongly suppressed. To our surprise, the most advanced technological methods, employing electrochemiluminescence or homogeneous time resolved fluorescence (HTRF) detection, were not capable of detecting the suppression induced by a glucose clamp (6 mmol/L) with or without atropine in five healthy male participants, whereas a radioimmunoassay and a spectrophotometry-based ELISA were. In summary, measurement of glucagon is challenging even when state-of-the-art immune-based technologies are used. Clinical researchers using glucagon as outcome measures may need to reconsider the validity of their chosen glucagon assay. The current study demonstrates that the most advanced approach is not necessarily the best when measuring a low-abundant peptide such as glucagon in humans.

AB - Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, important. We studied the ability of immunoassays based on four different technologies to detect changes in levels of glucagon under conditions where glucagon levels are strongly suppressed. To our surprise, the most advanced technological methods, employing electrochemiluminescence or homogeneous time resolved fluorescence (HTRF) detection, were not capable of detecting the suppression induced by a glucose clamp (6 mmol/L) with or without atropine in five healthy male participants, whereas a radioimmunoassay and a spectrophotometry-based ELISA were. In summary, measurement of glucagon is challenging even when state-of-the-art immune-based technologies are used. Clinical researchers using glucagon as outcome measures may need to reconsider the validity of their chosen glucagon assay. The current study demonstrates that the most advanced approach is not necessarily the best when measuring a low-abundant peptide such as glucagon in humans.

U2 - 10.1155/2016/8352957

DO - 10.1155/2016/8352957

M3 - Journal article

C2 - 26839899

VL - 2016

JO - Journal of Diabetes Research

JF - Journal of Diabetes Research

SN - 2314-6745

M1 - 8352957

ER -

ID: 156084438